Clinical trials: M-protein
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm…
- Trial name
- NCT05308602
- Testing
- SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Monoclonal Gammopathy of Unknown Significance
Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)
This is a study to investigate the functional consequences of paraprotein production in MGUS (Monoclonal Gammopathy of Unknown Significance).
- Trial name
- NCT02933021
- Testing
- Blood sample taken, Answering a lifestyle questionnaire, Follow-up phone call from researcher (two years after first visit)
- Where
- 9 sites in United Kingdom
- Volunteers
- 664 people
- Sponsor
- RxCelerate Ltd
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult…
- Trial name
- NCT04982068
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
COVID-19
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart…
- Trial name
- COVID-19 (NCT05468736)
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Where
- 94 sites in United States, Colombia and 8 more
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Novavax
IgA Nephropathy (IgAN), Membranous Nephropathy
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase.
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy
- Trial name
- NCT07389499
- Testing
- CD19-targeted iNKT Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
SARS-CoV-2 Infection
A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
This is a Phase 2, randomized, observer-blinded study evaluating the safety and immunogenicity of SARS-CoV-2 with Matrix-M™ Adjuvant in people living with human immunodeficiency virus (HIV) (PLWH) and HIV- negative adults…
- Trial name
- COVID-19 (NCT05112848)
- Testing
- NVX-CoV2373
- Where
- 7 sites in South Africa
- Volunteers
- 384 people
- Sponsor
- Novavax
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
The study is a randomized, double-blind, and positive-controlled Phase III booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with either one dose of Sinopharm…
- Trial name
- NCT05323461
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID - 19
PA-001 Ph.1 Study in Healthy and Elderly Subjects
This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts.
- Trial name
- NCT07518771
- Testing
- PA-001
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- PeptiDream Inc.
COVID-19
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
- Trial name
- NCT05313022
- Testing
- ZR-202-CoV
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
COVID-19 Pneumonia
COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05239923
- Testing
- Bacillus subtilis
- Where
- 2 sites in Hong Kong, Iran
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited